trending Market Intelligence /marketintelligence/en/news-insights/trending/Ns2O0gOCSvRm0Pa3wrje3w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA approves Astellas' antifungal drug for children younger than 4 months

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA approves Astellas' antifungal drug for children younger than 4 months

The U.S. Food and Drug Administration approved Astellas Pharma Inc.'s Mycamine to treat certain fungal infections in children younger than 4 months of age.

The regulator approved Astellas' supplemental new drug application to treat candidemia, acute disseminated candidiasis, candida peritonitis and abscesses without meningoencephalitis and\or ocular dissemination.

Invasive candidiasis is a fungal infection caused by a yeast called candida. Candidemia is a bloodstream infection with candida and is the most common form of invasive candidiasis.

According to an estimate by the Centers for Disease Control, about 25,000 new cases of candidemia occur in the U.S. each year.

Mycamine, or micafungin, is an injection that is already approved to treat candida fungus infections in adults and children who are at least 4 months old.

The FDA's approval is based on data from nine clinical studies that assessed the safety of different doses of the medication in 168 pediatric patients younger than 4 months of age.